Symbols / ABUS $4.30 +0.23% Arbutus Biopharma Corporation

Healthcare • Biotechnology • United States • NMS
ABUS Chart
About

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 840.56M
Enterprise Value 753.27M Income -33.50M Sales 14.08M
Book/sh 0.40 Cash/sh 0.47 Dividend Yield —
Payout 0.00% Employees 19 IPO —
P/E — Forward P/E -26.02 PEG —
P/S 59.69 P/B 10.80 P/C —
EV/EBITDA -28.23 EV/Sales 53.49 Quick Ratio 15.52
Current Ratio 15.73 Debt/Eq 5.47 LT Debt/Eq —
EPS (ttm) -0.17 EPS next Y -0.17 EPS Growth —
Revenue Growth -33.20% Earnings 2026-05-13 ROA -14.94%
ROE -38.52% ROIC — Gross Margin -79.23%
Oper. Margin -7.27% Profit Margin -237.88% Shs Outstand 195.48M
Shs Float 127.68M Short Float 12.08% Short Ratio 6.27
Short Interest — 52W High 5.10 52W Low 2.71
Beta 0.74 Avg Volume 2.21M Volume 1.05M
Target Price $5.60 Recom None Prev Close $4.29
Price $4.30 Change 0.23%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.60
Mean price target
2. Current target
$4.30
Latest analyst target
3. DCF / Fair value
$-1.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.30
Low
$4.90
High
$6.92
Mean
$5.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-14 main Chardan Capital Buy → Buy $5
2025-08-11 main Chardan Capital Buy → Buy $5
2025-03-28 main Chardan Capital Buy → Buy $5
2025-01-21 reit HC Wainwright & Co. Buy → Buy $5
2024-11-20 main Chardan Capital Buy → Buy $5
2024-11-18 reit HC Wainwright & Co. Buy → Buy $5
2024-11-07 reit HC Wainwright & Co. Buy → Buy $5
2024-11-07 main Chardan Capital Buy → Buy $5
2024-09-05 main Jefferies Buy → Buy $7
2024-08-02 main JMP Securities Market Outperform → Market Outperform $5
2024-06-07 reit HC Wainwright & Co. Buy → Buy $5
2024-06-06 reit HC Wainwright & Co. Buy → Buy $5
2024-06-05 main Chardan Capital Buy → Buy $4
2024-05-03 reit Chardan Capital Buy → Buy $4
2024-04-04 reit JMP Securities Market Outperform → Market Outperform $4
2024-03-01 reit Chardan Capital Buy → Buy $4
2024-03-01 main HC Wainwright & Co. Buy → Buy $5
2023-09-12 reit HC Wainwright & Co. Buy → Buy $6
2023-08-04 reit HC Wainwright & Co. Buy → Buy $6
2023-08-04 reit Chardan Capital Buy → Buy $6
News
RSS: Latest ABUS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-02 ANDROSKI LINDSAY J.D. Chief Executive Officer — 28,000 $0.00 $0
2026-02-02 NGUYEN TUAN Chief Financial Officer — 73,500 $0.00 $0
2025-02-14 NAFTZGER J CHRISTOPHER General Counsel — 54,300 $0.00 $0
2025-02-14 HASTINGS DAVID C Chief Financial Officer — 90,100 $0.00 $0
2025-02-14 SIMS KAREN Officer — 49,300 $0.00 $0
2025-02-04 NAFTZGER J CHRISTOPHER General Counsel — 11,333 $3.28 $37,206
2025-02-04 HASTINGS DAVID C Chief Financial Officer — 22,183 $3.28 $72,827
2025-02-04 SIMS KAREN Officer — 19,348 $3.28 $63,519
2024-08-14 MANCHESTER KEITH S Director — 8,846 $3.69 $32,637
2024-08-14 MANCHESTER KEITH S Director — 54,915 $0.56 $30,752
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
6.17
-65.98%
18.14
-53.51%
39.02
+255.11%
10.99
Operating Revenue
6.17
-65.98%
18.14
-53.51%
39.02
+255.11%
10.99
Operating Expense
76.14
-20.83%
96.17
-5.93%
102.24
+23.72%
82.64
Research And Development
54.04
-26.68%
73.70
-12.69%
84.41
+28.86%
65.50
Selling General And Administration
22.11
-1.63%
22.48
+26.02%
17.83
+4.07%
17.14
General And Administrative Expense
22.11
-1.63%
22.48
+26.02%
17.83
+4.07%
17.14
Other Gand A
22.11
-1.63%
22.48
+26.02%
17.83
+4.07%
17.14
Total Expenses
76.14
-20.83%
96.17
-5.93%
102.24
+23.72%
82.64
Operating Income
-69.97
+10.33%
-78.03
-23.43%
-63.22
+11.76%
-71.65
Total Operating Income As Reported
-76.32
+2.28%
-78.10
-19.32%
-65.46
+10.97%
-73.52
EBITDA
-68.40
+3.64%
-70.99
-14.75%
-61.86
+13.65%
-71.64
Normalized EBITDA
-62.01
+12.59%
-70.94
-19.02%
-59.60
+14.57%
-69.77
Reconciled Depreciation
1.38
-1.71%
1.40
-1.61%
1.43
-18.60%
1.75
EBIT
-69.78
+3.60%
-72.39
-14.39%
-63.29
+13.77%
-73.39
Total Unusual Items
-6.39
-14431.82%
-0.04
+98.05%
-2.25
-20.78%
-1.87
Total Unusual Items Excluding Goodwill
-6.39
-14431.82%
-0.04
+98.05%
-2.25
-20.78%
-1.87
Special Income Charges
-6.34
-9095.65%
-0.07
+96.91%
-2.23
-19.28%
-1.87
Restructuring And Mergern Acquisition
6.34
+9095.65%
0.07
-96.91%
2.23
+19.28%
1.87
Net Income
-69.92
+4.02%
-72.85
-4.89%
-69.46
+8.91%
-76.25
Pretax Income
-69.92
+4.02%
-72.85
-12.05%
-65.01
+14.74%
-76.25
Net Non Operating Interest Income Expense
6.45
+23.31%
5.23
+1022.10%
0.47
+117.07%
-2.73
Interest Expense Non Operating
0.14
-70.15%
0.46
-73.41%
1.73
-39.59%
2.86
Net Interest Income
6.45
+23.31%
5.23
+1022.10%
0.47
+117.07%
-2.73
Interest Expense
0.14
-70.15%
0.46
-73.41%
1.73
-39.59%
2.86
Interest Income Non Operating
6.58
+15.77%
5.69
+159.49%
2.19
+1625.98%
0.13
Interest Income
6.58
+15.77%
5.69
+159.49%
2.19
+1625.98%
0.13
Other Income Expense
-6.39
-14431.82%
-0.04
+98.05%
-2.25
-20.78%
-1.87
Gain On Sale Of Security
-0.05
-296.00%
0.03
+213.64%
-0.02
-540.00%
0.01
Tax Provision
0.00
0.00
-100.00%
4.44
0.00
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
+100.00%
-0.47
0.00
Net Income Including Noncontrolling Interests
-69.92
+4.02%
-72.85
-4.89%
-69.46
+8.91%
-76.25
Net Income From Continuing Operation Net Minority Interest
-69.92
+4.02%
-72.85
-4.89%
-69.46
+8.91%
-76.25
Net Income From Continuing And Discontinued Operation
-69.92
+4.02%
-72.85
-4.89%
-69.46
+8.91%
-76.25
Net Income Continuous Operations
-69.92
+4.02%
-72.85
-4.89%
-69.46
+8.91%
-76.25
Normalized Income
-63.53
+12.75%
-72.81
-7.58%
-67.67
+9.02%
-74.38
Net Income Common Stockholders
-69.92
+4.02%
-72.85
-4.89%
-69.46
+21.42%
-88.39
Otherunder Preferred Stock Dividend
—
—
0.00
-100.00%
12.14
Diluted EPS
-0.38
+13.64%
-0.44
+4.35%
-0.46
+44.58%
-0.83
Basic EPS
-0.38
+13.64%
-0.44
+4.35%
-0.46
+44.58%
-0.83
Basic Average Shares
185.61
+11.84%
165.96
+9.95%
150.94
+42.07%
106.24
Diluted Average Shares
185.61
+11.84%
165.96
+9.95%
150.94
+42.07%
106.24
Diluted NI Availto Com Stockholders
-69.92
+4.02%
-72.85
-4.89%
-69.46
+21.42%
-88.39
Earnings From Equity Interest
—
—
—
0.00
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
131.71
-8.79%
144.40
-26.11%
195.42
-4.43%
204.49
Current Assets
127.32
-3.57%
132.03
-12.65%
151.14
-5.93%
160.66
Cash Cash Equivalents And Short Term Investments
122.62
-2.68%
126.00
-14.23%
146.91
-5.41%
155.32
Cash And Cash Equivalents
36.33
+38.22%
26.29
-14.59%
30.78
-71.84%
109.28
Other Short Term Investments
86.29
-13.46%
99.72
-14.14%
116.14
+152.28%
46.03
Receivables
2.41
+35.64%
1.78
+31.36%
1.35
+50.39%
0.90
Accounts Receivable
2.41
+35.64%
1.78
+31.36%
1.35
+50.39%
0.90
Prepaid Assets
—
—
—
4.45
Other Current Assets
2.28
-46.23%
4.25
+47.81%
2.87
-35.34%
4.45
Total Non Current Assets
4.39
-64.51%
12.37
-72.06%
44.28
+1.04%
43.82
Net PPE
4.36
-28.46%
6.09
-10.63%
6.81
-15.62%
8.07
Gross PPE
17.35
-3.54%
17.99
+2.13%
17.61
+0.95%
17.45
Accumulated Depreciation
-13.00
-9.21%
-11.90
-10.17%
-10.80
-15.22%
-9.37
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.48
+21.99%
0.39
+0.00%
0.39
+1.30%
0.39
Other Properties
8.29
-8.03%
9.01
+4.34%
8.63
+1.58%
8.50
Leases
8.59
+0.00%
8.59
+0.00%
8.59
+0.32%
8.56
Investments And Advances
0.00
-100.00%
6.28
-83.18%
37.36
+4.69%
35.69
Other Non Current Assets
0.03
—
0.10
+68.85%
0.06
Total Liabilities Net Minority Interest
34.34
-10.53%
38.38
-34.46%
58.57
+67.11%
35.05
Current Liabilities
15.62
-30.55%
22.49
-31.56%
32.86
+192.82%
11.22
Payables And Accrued Expenses
7.56
-26.36%
10.27
-35.92%
16.03
+47.90%
10.84
Payables
2.32
-28.14%
3.22
-8.44%
3.52
+10.90%
3.17
Accounts Payable
2.32
-28.14%
3.22
-8.44%
3.52
+10.90%
3.17
Current Accrued Expenses
5.25
-25.54%
7.05
-43.66%
12.51
+63.22%
7.66
Current Debt And Capital Lease Obligation
0.48
+13.65%
0.42
+14.25%
0.37
-2.87%
0.38
Current Capital Lease Obligation
0.48
+13.65%
0.42
+14.25%
0.37
-2.87%
0.38
Current Deferred Liabilities
7.57
-35.79%
11.79
-28.35%
16.46
0.00
Current Deferred Revenue
7.57
-35.79%
11.79
-28.35%
16.46
0.00
Other Current Liabilities
—
—
—
0.03
Total Non Current Liabilities Net Minority Interest
18.72
+17.78%
15.90
-38.17%
25.71
+7.91%
23.82
Long Term Debt And Capital Lease Obligation
0.81
-39.99%
1.34
-26.01%
1.81
-18.65%
2.23
Long Term Capital Lease Obligation
0.81
-39.99%
1.34
-26.01%
1.81
-18.65%
2.23
Non Current Deferred Liabilities
2.86
0.00
-100.00%
6.00
0.00
Non Current Deferred Revenue
2.86
0.00
-100.00%
6.00
0.00
Other Non Current Liabilities
15.05
+3.44%
14.55
-18.68%
17.90
-17.13%
21.59
Stockholders Equity
97.37
-8.16%
106.02
-22.53%
136.85
-19.23%
169.44
Common Stock Equity
97.37
-8.16%
106.02
-22.53%
136.85
-19.23%
169.44
Capital Stock
1,410.03
+4.46%
1,349.82
+2.36%
1,318.74
+2.49%
1,286.64
Common Stock
1,410.03
+4.46%
1,349.82
+2.36%
1,318.74
+2.49%
1,286.64
Preferred Stock
—
—
—
0.00
Share Issued
189.96
+11.83%
169.87
+7.88%
157.46
+8.60%
144.99
Ordinary Shares Number
189.96
+11.83%
169.87
+7.88%
157.46
+8.60%
144.99
Additional Paid In Capital
82.05
+0.96%
81.27
+12.24%
72.41
+10.57%
65.48
Retained Earnings
-1,346.57
-5.48%
-1,276.65
-6.05%
-1,203.80
-6.12%
-1,134.35
Gains Losses Not Affecting Retained Earnings
-48.13
+0.59%
-48.42
+4.09%
-50.49
-4.45%
-48.34
Other Equity Adjustments
-48.13
+0.59%
-48.42
+4.09%
-50.49
-4.45%
-48.34
Total Equity Gross Minority Interest
97.37
-8.16%
106.02
-22.53%
136.85
-19.23%
169.44
Total Capitalization
97.37
-8.16%
106.02
-22.53%
136.85
-19.23%
169.44
Working Capital
111.70
+1.97%
109.54
-7.39%
118.28
-20.85%
149.44
Invested Capital
97.37
-8.16%
106.02
-22.53%
136.85
-19.23%
169.44
Total Debt
1.29
-27.09%
1.77
-19.16%
2.19
-16.34%
2.61
Capital Lease Obligations
1.29
-27.09%
1.77
-19.16%
2.19
-16.34%
2.61
Net Tangible Assets
97.37
-8.16%
106.02
-22.53%
136.85
-19.23%
169.44
Tangible Book Value
97.37
-8.16%
106.02
-22.53%
136.85
-19.23%
169.44
Available For Sale Securities
—
—
37.36
+4.69%
35.69
Held To Maturity Securities
0.00
-100.00%
6.28
-83.18%
37.36
—
Investmentin Financial Assets
0.00
-100.00%
6.28
-83.18%
37.36
+4.69%
35.69
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-64.85
+24.54%
-85.94
-143.06%
-35.36
+47.65%
-67.53
Cash Flow From Continuing Operating Activities
-64.85
+24.54%
-85.94
-143.06%
-35.36
+47.65%
-67.53
Net Income From Continuing Operations
-69.92
+4.02%
-72.85
-4.89%
-69.46
+8.91%
-76.25
Depreciation Amortization Depletion
1.38
-1.71%
1.40
-1.61%
1.43
-18.60%
1.75
Depreciation
1.38
-1.71%
1.40
-1.61%
1.43
-18.60%
1.75
Depreciation And Amortization
1.38
-1.71%
1.40
-1.61%
1.43
-18.60%
1.75
Other Non Cash Items
0.50
+114.99%
-3.34
+9.60%
-3.70
-166.81%
-1.39
Stock Based Compensation
8.99
-3.39%
9.30
+29.50%
7.18
+11.80%
6.42
Asset Impairment Charge
0.17
0.00
—
—
Operating Gains Losses
—
-0.02
—
-0.01
Net Foreign Currency Exchange Gain Loss
—
—
—
-0.01
Gain Loss On Sale Of PPE
0.00
+100.00%
-0.02
0.00
—
Change In Working Capital
-2.83
+84.48%
-18.23
-162.35%
29.24
+3061.41%
0.93
Change In Receivables
-0.63
-49.29%
-0.42
+6.40%
-0.45
-209.69%
0.41
Changes In Account Receivables
-0.63
-49.29%
-0.42
+6.40%
-0.45
-209.69%
0.41
Change In Prepaid Assets
2.30
+343.69%
-0.94
-138.81%
2.43
+337.07%
-1.02
Change In Payables And Accrued Expense
-2.71
+52.99%
-5.76
-210.39%
5.22
+172.95%
1.91
Change In Payable
—
—
5.22
+172.95%
1.91
Change In Account Payable
—
—
5.22
+172.95%
1.91
Change In Other Working Capital
-1.36
+87.27%
-10.66
-147.49%
22.45
—
Change In Other Current Liabilities
-0.43
+3.15%
-0.44
-9.63%
-0.41
-8.29%
-0.37
Investing Cash Flow
22.95
-54.80%
50.77
+167.75%
-74.94
-491.12%
-12.68
Cash Flow From Continuing Investing Activities
22.95
-54.80%
50.77
+167.75%
-74.94
-491.12%
-12.68
Net PPE Purchase And Sale
-0.18
+81.58%
-0.99
-92.97%
-0.51
+36.71%
-0.81
Purchase Of PPE
-0.18
+81.94%
-1.01
-96.88%
-0.51
+36.71%
-0.81
Sale Of PPE
0.00
-100.00%
0.02
0.00
—
Capital Expenditure
-0.18
+81.94%
-1.01
-96.88%
-0.51
+36.71%
-0.81
Net Investment Purchase And Sale
23.13
-55.31%
51.76
+169.54%
-74.43
-527.10%
-11.87
Purchase Of Investment
-141.51
-75.77%
-80.51
+38.27%
-130.43
-58.64%
-82.22
Sale Of Investment
164.64
+24.47%
132.27
+136.20%
56.00
-20.40%
70.35
Financing Cash Flow
52.00
+69.66%
30.65
-3.67%
31.81
-76.82%
137.24
Cash Flow From Continuing Financing Activities
52.00
+69.66%
30.65
-3.67%
31.81
-76.82%
137.24
Net Common Stock Issuance
44.12
+47.81%
29.85
+46.88%
20.32
-84.91%
134.66
Proceeds From Stock Option Exercised
7.87
+890.31%
0.80
-93.08%
11.49
+346.91%
2.57
Changes In Cash
10.09
+323.52%
-4.52
+94.25%
-78.48
-237.63%
57.03
Effect Of Exchange Rate Changes
-0.05
-296.00%
0.03
+213.64%
-0.02
-540.00%
0.01
Beginning Cash Position
26.29
-14.59%
30.78
-71.84%
109.28
+109.15%
52.25
End Cash Position
36.33
+38.22%
26.29
-14.59%
30.78
-71.84%
109.28
Free Cash Flow
-65.03
+25.20%
-86.94
-142.40%
-35.87
+47.52%
-68.34
Amortization Of Securities
-3.13
-42.76%
-2.20
-3966.67%
-0.05
-105.41%
1.00
Common Stock Issuance
44.12
+47.81%
29.85
+46.88%
20.32
-84.91%
134.66
Issuance Of Capital Stock
44.12
+47.81%
29.85
+46.88%
20.32
-84.91%
134.66
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category